| 前收盘价格 | 28.57 |
| 收盘价格 | 28.82 |
| 成交量 | 6,052 |
| 平均成交量 (3个月) | 21,940 |
| 市值 | 51,387,876 |
| 价格/销量 (P/S) | 2.12 |
| 股市价格/股市净资产 (P/B) | 3.89 |
| 52周波幅 | |
| 利润日期 | 11 Aug 2025 - 15 Aug 2025 |
| 营业毛利率 | -15.45% |
| 营业利益率 (TTM) | -17.43% |
| 稀释每股收益 (EPS TTM) | -2.06 |
| 季度收入增长率 (YOY) | 43.60% |
| 总债务/股东权益 (D/E MRQ) | 19.09% |
| 流动比率 (MRQ) | 0.760 |
| 营业现金流 (OCF TTM) | 1.06 M |
| 杠杆自由现金流 (LFCF TTM) | 1.76 M |
| 资产报酬率 (ROA TTM) | -10.90% |
| 股东权益报酬率 (ROE TTM) | -25.29% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Precipio, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.40 |
|
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. It focuses on improving cancer diagnostics, particularly hematologic malignancies. Its objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, and Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division and the Products Division. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 14.13% |
| 机构持股比例 | 7.46% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合